Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IFRX
HoldInflaRx N.V. · Healthcare · Germany · $329M · Avg Vol: $2M/d
39
StockRankGet insider-trade alerts
Q
29
V
31
M
69
P/E (TTM)
—
ROE
-38.5%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 73.1K | 0.2M | 34.0K | -31.8% | -11.8K | — | — | — |
| EPS | -0.24 | -0.36 | -0.36 | -0.39 | — | -0.58 | -0.31 | -0.40 | — |
| Shares | 147.3M | 147.3M | 147.3M | 147.3M | 0.0% | 147.4M | — | — | — |
| Debt | 1.6M | 1.3M | 0.9M | 1.0M | -12.9% | 1.0M | — | — | — |
| Equity | 102.4M | 118.9M | 71.2M | 48.2M | -22.2% | — | — | — | — |
| Op CF | -39.1M | -43.8M | -56.3M | -40.9M | — | -27.7M | — | — | — |
| Inv CF | 22.4M | -20.5M | 60.7M | 3.7M | — | — | — | — | — |
| Fin CF | 2.2M | 61.4M | 0.4M | 38.6M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+22.5%
SMA 50SMA 200
Close
$2.23
RSI (14)
61.7
52W High
$2.95
From 52W High
0.8%
SCORE BREAKDOWN
Quality
29
ROIC
-92.4%7.7
ROE
-38.5%23.4
GP/Assets
-9.0%7.0
Op. Margin
352965.0%100.0
FCF/Assets
-43.2%8.5
Piotroski
26.0
Int. Cover
-50.0x6.2
D/E Ratio
0.01x87.7
Current Ratio
8.22x82.8
Value
31
P/E (TTM)
—N/A
EV/EBITDA
-4.8x25.0
P/FCF
—N/A
P/B
1.8x65.2
P/S
-30264.7x25.0
Div Yield
—N/A
Momentum
69
52W High %
76%58.2
RS 6M
130%98.0
SMA 50/200
1.33x94.9
EPS Rev 4W
+5.5%83.8
EPS Rev 12W
—N/A
EPS Improve
+30%43.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$329M
P/E (Forward)
-6.0x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IFRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IFRX | InflaRx N.V.(you) | $329M | 39 | Hold |
| FYB.DE | Formycon AG | $380M | 36 | Hold |
| VRXA | Veraxa Biotech AG | $191M | 1 | Strong Sell |
| IMTX | Immatics N.V. | $1.4B | 11 | Strong Sell |
| 22UA.DE | BioNTech SE | $25.9B | 43 | Hold |
| NNNN | Anbio Biotechnology | $337M | 19 | Strong Sell |
| EVO | Evotec SE | $679M | 23 | Sell |
| ILM1.DE | Medios AG | $326M | 74 | Buy |
| QUCY | Quantum Cyber N.V. | $119M | 21 | Sell |
| GXI.DE | Gerresheimer AG | $1.1B | 56 | Hold |
Peer medians: ROE 7.2% · P/E 16.5x · Gross margin 45.4%